Onyx Pharmaceuticals Inc (ONXX)

[surf1944]

9:03AM Onyx Pharma initiates a Phase 3 Carfilzomib combination trial in Relapsed Multiple Myeloma (ONXX) 20.79 : Co announces that it has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment and received Scientific Advice from the European Medicines Agency on the design and planned analysis of the ASPIRE trial.